US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

BerGenBio ASA: Results for the Second Quarter and First Half 2019

· Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy · Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those with low or no PD-L1 expression. · Recruitment completed for second stage Phase II bemcentinib and KEYTRUDA® combo trial in patients with advanced NSCLC (BGB008) · Private placement completed,

BerGenBio presents preliminary Phase II clinical data at EHA 24: bemcentinib in combination with low dose chemotherapy yields durable responses in AML patients unfit for intensive chemotherapy

· Two posters to be presented at the 2019 annual congress of the European Hematology Association on 14th June · Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy shows significant efficacy · Preliminary responses reported in 6/14 (43%) patients, with CR/CRi in 4/14 (29%) patients; this is substantially higher than previously observed/historical benchmarks in single-agent cytarabine (low-dose chemotherapy) · Median relapse-free survival 7.9 months in CR/CRi patients (

BerGenBio presents new Phase II clinical data that bemcentinib in combination with low dose chemotherapy improves efficacy and duration of survival in elderly AML patients at ASCO 2019

· Phase II trial evaluating bemcentinib in combination with low-intensity chemotherapy in elderly AML patients unfit for intensive therapy shows promising efficacy · 6 out of 13 (46%) patients receiving LDAC combination achieved an Overall Response Rate (ORR) of 46% · 3 out of 12 evaluable patients receiving decitabine combination achieved an ORR of 25% · ORR significantly higher than previously observed/historical benchmarks in single-agent cytarabineChicago, USA, 03 June 2019 – BerGenBio ASA (OSE:BGBIO) today presents data showing significant efficacy in Phase II clinical trials (

BerGenBio presents new preliminary clinical and biomarker data showing durable response & median survival rates in Phase II trial with bemcentinib and KEYTRUDA in pts with advanced NSCLC at ASCO 2019

· Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy · Promising clinical activity continues to be seen, particularly in patients with AXL positive tumours including those with low or no PD-L1 expressionChicago, USA, 02 June 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, today presents updated data from its Phase II

BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 · Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety, response rates and overall survival · Acute Myeloid Leukaemia (AML) trial of bemcentinib in combination with low dose AraC chemotherapy or decitabine reported safety and rapid, durable complete response ratesBergen, Norway, 15 May 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase

BerGenBio ASA: Results for the First Quarter 2019

· Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia · Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® · Anti-AXL antibody, BGB149, commenced phase I safety and pharmacokinetic clinical trial.Bergen, Norway, 08 May 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer

BerGenBio to present NSCLC and AML clinical data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Phase II data in AML combining bemcentinib with low-dose chemotherapy and NSCLC combining with KEYTRUDA · Accepted for presentation at ASCO in June 2019Bergen, Norway, 23 April 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces that the Company and its collaborators will present new interim clinical and biomarker data from its extensive Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, at the 2019 annual meeting of the American

BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS

· Phase II monotherapy study of bemcentinib in high-risk MDS & AML · Will enrol up to 43 patients at leading MDS centres across Europe · Investigator sponsored trial led by Prof. Uwe PlatzbeckerBergen, Norway, Jan 4th 2019 - BerGenBio ASA (OSE: BGBIO), announces that the first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who have failed first-line treatment with hypomethylating agents. The trial may also enrol a proportion of

BerGenBio reports 43% response rate with bemcentinib monotherapy in AXL positive R/R AML/MDS patients at ASH

· 43% CR/CRi/CRp rate with bemcentinib monotherapy reported in AXL biomarker positive R/R AML/MDS patients (6 out of 14) · Phase II trial continues in combination with chemotherapeutics in first line AML · Bemcentinib with decitabine cohort has completed recruitment, data will be submitted for presentation at upcoming medical congressBergen, Norway, 3 Dec 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, today announced that it presented a

BerGenBio to present interim clinical and biomarker data with selective AXL inhibitor bemcentinib in AML and MDS at EHA

Bergen, Norway, 18 May 2018 – BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators will present interim clinical data from its Phase II clinical development programme with bemcentinib, a selective, oral AXL inhibitor, in acute myeloid leukaemia (AML) and myeloid dysplastic syndrome (MDS) at the 23rd Congress of the European Hematology Association (EHA) in Stockholm (14-17 June 2018). Abstracts are now available online at https://ehaweb.org and details of the presentations are below. The posters presented at EHA will be made available on www.bergenbio.com in the

BerGenBio ASA: Results for the First Quarter 2018

Bergen, Norway, 15 May 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2018. A presentation of the results by the Company’s management will take place today at 10.00 am CET in Oslo – details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are pleased with the progress made during Q1 2018. Patient recruitment into our global Phase II clinical proof-of-concept trials with bemcentinib is progressing well and we

BerGenBio participation at upcoming healthcare investor and life sciences industry conferences

Bergen, Norway, 14 May 2018– BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will be participating at the following upcoming conferences.· 14-16 May, Bio€quity Europe 2018 (Ghent, Belgium)* · 23 May, ABG Sundal Collier Cancer Seminar (Stockholm, Sweden)* · 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)* · 4 June, Norne Securities Conference (Bergen, Norway)*  · 1-5 June, 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago,

BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy

· Favourable interim safety data reported across three phase II clinical trials with bemcentinib in combination with KEYTRUDA® (pembrolizumab) · Immune response demonstrated in AML patients treated with bemcentinib monotherapy in phase II clinical trial · Two posters featuring four of BerGenBio’s six phase II clinical trials with selective AXL inhibitor bemcentinib presented at the ASCO-SITC Clinical Immuno-Oncology SymposiumBergen, Norway, January 29, 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing bemcentinib as a potential

BerGenBio Presents Update on Ph II Clinical Trial with Selective AXL Inhibitor BGB324 in Relapsed/Refractory AML Patients at 59th ASH Annual Meeting

35 relapsed/refractory AML and MDS patients received BGB324 as monotherapy; two CRi and five PR were observed, and seven patients stayed on treatment for more than four months. Three novel and proprietary predictive biomarker candidates were identified.Bergen, Norway, 11 Dec 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, today announced that it presented an update on the BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor BGB324 in

Clinical Study with BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, Featured at the 2017 American Society of Hematology Annual Meeting

Bergen, Norway, 1 Nov 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that data and analysis from its Phase Ib/II clinical trial with BGB324 in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), has been selected for presentation at the 59th ASH Annual Meeting and Exposition in Atlanta, USA (9-12 Dec 2017).The presentation reports on the effect of BGB324 treatment on blood plasma proteins and their relationship to treatment outcome, as a

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media